Fair question. Individual customer inquiries (so long as they are accurate) to one's own PBM/insurer I would think need not be coordinated with Amarin (though an email to IR wouldn't hurt). Anything coordinated by a shareholder group might present a different set of issues, and I would think a general inquiry to the company asking if it would have any objection (not asking for their participation or approval, just whether they would object) might be in order.
In my prior post I hypothesized advocating for elevation to tier 2; I should have said tier 3 (preferred brand-name drug).
Market Data 
Markets 
AI
